Key result
Development of ≥ grade 2 hypertension was associated with significantly longer progression-free survival (31.5 vs 14.9 months) in prostate cancer patients treated with bevacizumab.
Why the study?
Does the development of hypertension or hand-foot skin reactions, and VEGFR2 genotype, predict progression-free and overall survival in patients with solid tumors treated with bevacizumab and/or sorafenib?
Population
178 patients with solid tumors enrolled in six phase I or II clinical trials at the National Cancer Institute.
Comparison
Sorafenib and/or bevacizumab with or without… vs Patients who did not develop ≥ grade 2…
Design
Cohort
Authors
Loading...
Hypertension may signal bevacizumab benefit in prostate cancer; leaves open biomarker utility across tumors pending prospective validation.
Cohort (n=178)
Does the development of hypertension or hand-foot skin reactions, and VEGFR2 genotype, predict progression-free and overall survival in patients with solid tumors treated with bevacizumab and/or sorafenib?
Absolute Event Rate: 31.5% vs 14.9%
p-value: p=0.0009
The development of hypertension and hand-foot skin reactions during anti-VEGF therapy with bevacizumab and/or sorafenib may serve as clinical biomarkers for improved progression-free and overall survival in patients with solid tumors.
Jain et al. (2010) conducted a cohort in Solid tumors (n=178). Development of ≥ grade 2 hypertension vs. < grade 2 hypertension was evaluated on Progression-free survival (PFS) (p=0.0009). Development of ≥ grade 2 hypertension was associated with significantly longer progression-free survival (31.5 vs 14.9 months) in prostate cancer patients treated with bevacizumab.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: